What do systematic reviews say?

Intervention not reported

It is very uncertain whether the intervention changes myocardial injury (hospital stay) (very low certainty).

• Effects of interventions targeting the systemic inflammatory response to cardiac surgery on clinical outcomes in adults 2023 · Cochrane Headline outcomes only
  RR 1.04 [0.95, 1.14]
  86 studies · 23118 participants
  Very low

Intervention not reported

The intervention showed no clear difference in kidney injury (safety outcome) (hospital stay) (low certainty).

• Effects of interventions targeting the systemic inflammatory response to cardiac surgery on clinical outcomes in adults 2023 · Cochrane Headline outcomes only
  RR 1.06 [0.96, 1.16]
  79 studies · 23103 participants
  Low

Intervention not reported

The intervention showed no clear difference in surgical Site Infection (hospital stay) (low certainty).

• Effects of interventions targeting the systemic inflammatory response to cardiac surgery on clinical outcomes in adults 2023 · Cochrane Headline outcomes only
  RR 0.92 [0.83, 1.01]
  40 studies · 19368 participants
  Low

Intervention not reported

• Effects of interventions targeting the systemic inflammatory response to cardiac surgery on clinical outcomes in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  148 studies · 15547 participants
  Very low

Class I and/or III antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

Class I antiarrhythmics showed no clear difference in recurrence of atrial tachyarrhythmias compared with control (low certainty).

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  RR 0.54 [0.25, 1.19]
  1 study · 125 participants
  Low

Class I antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 participants
  GRADE not reported

Class I antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 participants
  GRADE not reported

Class III antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class III antiarrhythmics vs control

Class III antiarrhythmics showed no clear difference in recurrence of atrial tachyarrhythmias compared with control (low certainty).

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  RR 0.82 [0.62, 1.09]
  2 studies · 318 participants
  Low

Class III antiarrhythmics vs control

It is very uncertain whether class III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  Peto OR 0.96 [0.06, 15.5]
  1 study · 212 participants
  Very low

Class I and/or III antiarrhythmics vs control

Class I and/or III antiarrhythmics probably leads to lower recurrence of atrial tachyarrhythmias compared with control (moderate certainty).

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  RR 0.85 [0.78, 0.93]
  5 studies · 2591 participants
  Moderate

Class III antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class III antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class III antiarrhythmics vs control

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 participants
  GRADE not reported

Class III antiarrhythmics vs control

It is very uncertain whether class III antiarrhythmics changes all‐cause mortality compared with control (very low certainty).

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  Peto OR 0.13 [0, 6.57]
  1 study · 212 participants
  Very low